Mark Shearman - Feb 10, 2022 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, CHIEF SCIENTIFIC OFFICER
Signature
/s/ Mark Shearman
Stock symbol
EDIT
Transactions as of
Feb 10, 2022
Transactions value $
$0
Form type
4
Date filed
2/11/2022, 03:21 PM
Previous filing
Dec 23, 2021
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +31.7K +75.89% $0.00 73.5K Feb 10, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +93.4K $0.00 93.4K Feb 10, 2022 Common Stock 93.4K $17.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026.
F2 This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026.